{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:02:55Z","timestamp":1794013375007,"version":"4.8.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jdin.2026.04.004","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:54:22Z","timestamp":1776066862000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study"],"prefix":"10.1016","volume":"26","author":[{"given":"Danielle","family":"Bar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Pavlotsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviv","family":"Barzilai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jdin.2026.04.004_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jdin.2026.04.004_bib2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.jdin.2026.04.004_bib3","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00403-014-1495-1","article-title":"Impact of obesity on the efficacy of ustekinumab in Japanese patients with psoriasis: a retrospective cohort study of 111 patients","volume":"306","author":"Yanaba","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"10.1016\/j.jdin.2026.04.004_bib4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/09546634.2019.1626973","article-title":"Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis","volume":"31","author":"Pinter","year":"2020","journal-title":"J Dermatolog Treat"},{"issue":"13","key":"10.1016\/j.jdin.2026.04.004_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdin.2026.04.004_bib6","article-title":"GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study","volume":"3","author":"Olbrich","year":"2025","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jdin.2026.04.004_bib7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jaad.2025.06.022","article-title":"Glucagon-like peptide-1 receptor agonist use in patients with psoriasis is associated with lower incidence of atherosclerotic cardiovascular disease: a retrospective cohort study using TriNetX","volume":"93","author":"Sontam","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdin.2026.04.004_bib8","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaad.2025.12.035","article-title":"Glucagon-like peptide-1 receptor agonist therapy in patients with psoriasis is associated with decreased risk of psoriatic arthritis: a retrospective cohort study from the TriNetX database","volume":"94","author":"Hsiao","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2026.04.004_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/09546634.2013.865009","article-title":"The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials","volume":"26","author":"Langley","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdin.2026.04.004_bib10","article-title":"Mediterranean diet and patients with psoriasis: the MEDIPSO randomized clinical trial","volume":"24","author":"Perez-Bootello","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2026.04.004_bib11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bjd.12735","article-title":"Diet and physical exercise in psoriasis: a randomized controlled trial","volume":"170","author":"Naldi","year":"2014","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2026.04.004_bib12","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/nu15071698","article-title":"Modulation of dietary fatty acids in an open-label study improves psoriasis and dampens the inflammatory activation status","volume":"15","author":"Saalbach","year":"2023","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.jdin.2026.04.004_bib13","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3825","article-title":"Impact of bariatric surgery on moderate to severe psoriasis: a retrospective nationwide registry study","volume":"101","author":"Laskowski","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"10.1016\/j.jdin.2026.04.004_bib14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.soard.2024.07.011","article-title":"The long-term impact of bariatric surgery on psoriasis symptoms and severity: a prospective observational study","volume":"20","author":"Hosseininasab","year":"2024","journal-title":"Surg Obes Relat Dis"},{"issue":"10","key":"10.1016\/j.jdin.2026.04.004_bib15","article-title":"Effects of weight loss on psoriasis: a review of clinical trials","volume":"10","author":"Alotaibi","year":"2018","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jdin.2026.04.004_bib16","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaad.2014.02.012","article-title":"Diet and psoriasis, part I: impact of weight loss interventions","volume":"71","author":"Debbaneh","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2026.04.004_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2026.04.004_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3945\/ajcn.115.125849","article-title":"Long-term effects of weight reduction on the severity of psoriasis in a cohort derived from a randomized trial: a prospective observational follow-up study","volume":"104","author":"Jensen","year":"2016","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jdin.2026.04.004_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2147\/CCID.S147236","article-title":"Associations between body mass index and severity of psoriasis","volume":"10","author":"Sobhan","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2026.04.004_bib20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","volume":"33","author":"Lin","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.jdin.2026.04.004_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/biom15010046","article-title":"Effects of semaglutide treatment on psoriatic lesions in obese patients with type 2 diabetes mellitus: an open-label, randomized clinical trial","volume":"15","author":"Petkovi\u0107-Dabi\u0107","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.jdin.2026.04.004_bib22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.jdin.2026.04.004_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/bjd.12886","article-title":"Improvement of psoriasis during glucagon-like peptide-1 analogue therapy in type 2 diabetes is associated with decreasing dermal \u03b3\u03b4 T-cell number: a prospective case-series study","volume":"171","author":"Buysschaert","year":"2014","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2026.04.004_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial","volume":"29","author":"Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2026.04.004_bib25","article-title":"Two birds one stone: semaglutide is highly effective against severe psoriasis in a type 2 diabetic patient","volume":"2021","author":"Costanzo","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"1","key":"10.1016\/j.jdin.2026.04.004_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","article-title":"Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide","volume":"51","author":"Faurschou","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jdin.2026.04.004_bib27","first-page":"143","article-title":"Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review","volume":"14","author":"Haran","year":"2024","journal-title":"Psoriasis (Auckl)"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726000532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328726000532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T15:30:29Z","timestamp":1782747029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328726000532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":27,"alternative-id":["S2666328726000532"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2026.04.004","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of glucagon-like peptide 1 analogues in psoriasis: A cohort study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2026.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}